OREGA announces licensing of its first in class CD39 checkpoint inhibitor

Four projects supported by our foundation
5 February 2016
Graftys : initiation of post Marketing Surveillance program
16 November 2015

OREGA announces licensing of its first in class CD39 checkpoint inhibitor

OREGA has entered into a worldwide licensing agreement with Innate Pharma.